eli lilly trials retatrutide Lilly's cuts weight by 17% in diabetes trial Lilly's triple agonist delivers up

Peptide compound studied for appetite signals, gastric emptying, insulin dynamics, and energy expenditure

Combine weight loss medications with personalized lifestyle plans that include nutrition counseling, liposuction options, and long-term wellness strategies

Kaplan-Meier Estimates of Primary and Secondary Outcomes in Patients with DM and HFpEF Treated with GLP-1 RAs or SGLT2 Inhibitors

Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction

Participants in the retatrutide trials "report decreased appetite or increased satiety," Jastreboff said

This suggests that GLP-1 agonists may enhance the therapeutic effects of progestins, potentially leading to better outcomes in managing endometriosis symptoms and reducing the risk of associated cancers